Sørensen, Per Soelberg
Article History
First Online: 4 December 2015
Competing interests
: The author has received personal compensation for serving on scientific advisery boards, steering committees or independent data-monitoring boards for Biogen Idec, Merck Serono, Novartis, Genzyme, Teva Pharmaceutical Industries, GlaxoSmithKline, MedDay Pharmaceuticals and Forward Pharma, and has received speaker honouraria from Biogen Idec, Merck Serono, Teva Pharmaceutical Industries, Genzyme and Novartis. His department has received research support from Biogen Idec, Merck Serono, Teva Pharmaceutical Industries, Baxter, Sanofi Aventis, Novartis, Bayer, RoFAR, Roche and Genzyme.